Aliases & Classifications for Breast Disease

MalaCards integrated aliases for Breast Disease:

Name: Breast Disease 12 15 17
Breast Diseases 54 42 43 71

Classifications:



External Ids:

Disease Ontology 12 DOID:3463
ICD9CM 34 610-612.99
MeSH 43 D001941
NCIt 49 C26709
SNOMED-CT 67 79604008
UMLS 71 C0006145

Summaries for Breast Disease

MedlinePlus : 42 Most women experience breast changes at some time. Your age, hormone levels, and medicines you take may cause lumps, bumps, and discharges (fluids that are not breast milk). If you have a breast lump, pain, discharge or skin irritation, see your health care provider. Minor and serious breast problems have similar symptoms. Although many women fear cancer, most breast problems are not cancer. Some common breast changes are Fibrocystic breast changes - lumpiness, thickening and swelling, often just before a woman's period Cysts - fluid-filled lumps Fibroadenomas - solid, round, rubbery lumps that move easily when pushed, occurring most in younger women Intraductal papillomas - growths similar to warts near the nipple Blocked milk ducts Milk production when a woman is not breastfeeding NIH: National Cancer Institute

MalaCards based summary : Breast Disease, also known as breast diseases, is related to microglandular adenosis and hypertrophy of breast, and has symptoms including pruritus, exanthema and pelvic pain. An important gene associated with Breast Disease is PRLR (Prolactin Receptor), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Acetylcholine and Tamoxifen have been mentioned in the context of this disorder. Affiliated tissues include breast, lymph node and thyroid, and related phenotypes are endocrine/exocrine gland and homeostasis/metabolism

Disease Ontology : 12 A thoracic disease that is located in the breast.

Wikipedia : 74 Breast diseases make up a number of conditions. The most common symptoms are a breast mass, breast pain,... more...

Related Diseases for Breast Disease

Diseases related to Breast Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 406, show less)
# Related Disease Score Top Affiliating Genes
1 microglandular adenosis 34.0 TP53 PGR ESR1 ERBB2
2 hypertrophy of breast 33.0 TP53 PGR ESR1 ERBB2 CYP19A1 BRCA2
3 breast fibroadenoma 32.1 TP53 TFF1 PGR ESR1 ERBB2 CYP19A1
4 breast cancer 32.0 VEGFA TP53 TFF1 RHOC PRLR PGR
5 in situ carcinoma 31.9 TP53 PGR ESR1 ERBB2 EGF CYP19A1
6 ductal carcinoma in situ 31.7 VEGFA TP53 PGR ESR2 ESR1 ERBB2
7 gynecomastia 31.7 PGR ESR2 ESR1 ERBB2 CYP19A1
8 breast cyst 31.5 IGF1 EGF CYP19A1 CTSD
9 intraductal papilloma 31.4 PGR ESR1 ERBB2
10 lobular neoplasia 31.3 TP53 PRLR PGR ESR2 ESR1 ERBB2
11 mammary paget's disease 31.1 PGR ESR1 ERBB2
12 breast ductal carcinoma 31.1 VEGFA TP53 TFF1 PGR ESR2 ESR1
13 mammographic density 31.0 PGR IGFBP3 IGF1 ESR1 CYP1B1 CYP1A1
14 insulin-like growth factor i 31.0 IGFBP3 IGF1 ESR1 EGF
15 adenocarcinoma 31.0 VEGFA TP53 ERBB2 EGF BRCA2
16 endometriosis 31.0 VEGFA TP53 PGR MIR199A1 ESR2 ESR1
17 female breast cancer 30.9 TP53 PGR IGF1 ESR1 ERBB2 CYP1A1
18 anovulation 30.8 IGFBP3 IGF1 CYP19A1
19 leiomyoma 30.8 PGR ESR2 ESR1 EGF CYP19A1 COMT
20 galactorrhea 30.8 PRLR IGF1
21 estrogen excess 30.8 PGR ESR2 ESR1 CYP19A1
22 tubular adenocarcinoma 30.7 PGR ESR1 ERBB2
23 bilateral breast cancer 30.7 PGR ESR1 ERBB2 BRCA2 BRCA1
24 sporadic breast cancer 30.7 TP53 PGR ESR2 ESR1 ERBB2 CYP19A1
25 cowden syndrome 30.7 TP53 ERBB2 BRCA2 BRCA1
26 breast malignant phyllodes tumor 30.6 TP53 PGR ESR1 ERBB2
27 apocrine adenocarcinoma 30.6 TP53 PGR ESR1 ERBB2
28 meningioma, familial 30.6 VEGFA TP53 PGR IGF1 ESR1 ERBB2
29 inflammatory breast carcinoma 30.6 RHOC PGR ESR1 ERBB2
30 cystitis 30.6 VEGFA TP53 IGF1 EGF
31 neurofibromatosis, type ii 30.6 VEGFA TP53 PGR ERBB2 EGF
32 cervical cancer 30.6 VEGFA TP53 IGFBP3 ESR1 ERBB2 EGF
33 vulvar disease 30.5 TP53 PGR ERBB2
34 li-fraumeni syndrome 30.5 TP53 ESR1 ERBB2 BRCA2 BRCA1
35 body mass index quantitative trait locus 11 30.5 VEGFA TP53 MIR199A1 IGFBP3 IGF1 ESR1
36 prostatic hypertrophy 30.5 PGR ESR1 EGF CYP19A1
37 fallopian tube carcinoma 30.5 VEGFA TP53 PGR ESR1 ERBB2 BRCA2
38 hyperandrogenism 30.5 IGFBP3 IGF1 CYP19A1
39 hereditary breast ovarian cancer syndrome 30.5 TP53 ERBB2 BRCA2 BRCA1
40 gastric cancer 30.5 VEGFA TP53 TFF1 PGR MIR199A1 IGF1
41 breast carcinoma in situ 30.5 VEGFA TP53 PGR ESR1 ERBB2 EGF
42 rare malignant breast tumor 30.4 BRCA2 BRCA1
43 ovarian disease 30.4 VEGFA TP53 PGR MIR199A1 IGF1 ESR2
44 rare non-malformative breast disease 12.1
45 mastitis 11.8
46 diabetic mastopathy 11.4
47 infant gynecomastia 11.3
48 breast abscess 11.3
49 multiple fibroadenomas of the breast 11.1
50 gastric adenocarcinoma 11.0 VEGFA TP53 TFF1 IGF1 ESR2 ESR1
51 mixed cell adenoma 10.9 IGF1 EGF CTSD
52 endometrial adenocarcinoma 10.9 VEGFA TP53 PGR IGF1 ESR2 ESR1
53 fat necrosis of breast 10.9
54 breast angiomatosis 10.9
55 breast adenocarcinoma 10.9 TP53 PGR ESR1 ERBB2 EGF CYP1A1
56 lipid-rich carcinoma 10.9 PRLR PGR ESR1 ERBB2
57 mucinous adenocarcinoma 10.9 VEGFA TP53 PGR ESR2 ESR1 ERBB2
58 comedo carcinoma 10.9 TP53 PGR ESR1 ERBB2
59 disorders of sexual development 10.9 IGFBP3 IGF1 ESR2 ESR1 CYP19A1
60 esophageal adenosquamous carcinoma 10.9 TP53 IGFBP3 ERBB2
61 cerebral meningioma 10.9 PRLR PGR IGF1 EGF
62 pancreatic ductal carcinoma 10.9 VEGFA TP53 ERBB2 EGF
63 gastric ulcer 10.9 VEGFA TP53 TFF1 EGF
64 colorectal adenoma 10.9 VEGFA TP53 IGFBP3 IGF1
65 vaginal cancer 10.9 TP53 PGR ESR2 ESR1
66 carcinosarcoma 10.9 TP53 PGR ERBB2
67 cervical adenocarcinoma 10.9 TP53 PGR ESR1 ERBB2 EGF
68 adenosarcoma 10.9 TP53 PGR ESR1 ERBB2
69 bartholin's gland adenoma 10.9 TP53 PGR ESR1
70 bartholin's gland benign neoplasm 10.9 TP53 PGR ESR1
71 pheochromocytoma 10.9 VEGFA IGF1 ESR1 ERBB2 EGF COMT
72 myeloma, multiple 10.9 VEGFA TP53 MIR199A1 IGF1 ESR1 ERBB2
73 vestibular gland benign neoplasm 10.9 TP53 PGR ESR1
74 aromatase excess syndrome 10.9 IGF1 ESR2 ESR1 CYP19A1
75 endocervical carcinoma 10.9 TP53 PGR ESR1 ERBB2
76 sweat gland disease 10.9 TP53 PGR ESR1 ERBB2
77 sweat gland cancer 10.9 TP53 PGR ESR1 ERBB2
78 glassy cell carcinoma of the cervix 10.9 PGR ESR1 ERBB2
79 uterine carcinosarcoma 10.9 TP53 PGR ESR2 ESR1 ERBB2
80 intrahepatic cholestasis of pregnancy 10.9 TP53 ESR2 ESR1 CYP1A1
81 donohue syndrome 10.9 IGFBP3 IGF1 EGF
82 short syndrome 10.9 TP53 PGR ESR1 ERBB2
83 cell type benign neoplasm 10.9 VEGFA TP53 MIR199A1 IGF1 ESR1
84 uterine body mixed cancer 10.9 TP53 ESR1 ERBB2
85 endocervical adenocarcinoma 10.9 TP53 PGR ESR1 ERBB2
86 eye disease 10.9 VEGFA TP53 MIR199A1 IGFBP3 IGF1 EGF
87 ovarian seromucinous carcinoma 10.9 TP53 PGR ESR1
88 lipid-rich breast carcinoma 10.9 PRLR PGR ERBB2
89 premature ovarian failure 1 10.9 IGFBP3 IGF1 ESR2 ESR1 CYP19A1
90 ewing sarcoma 10.9 VEGFA TP53 IGFBP3 IGF1 ERBB2 BRCA1
91 breast scirrhous carcinoma 10.9 PGR ESR1 ERBB2
92 oncocytic breast carcinoma 10.9 PGR ESR1 ERBB2
93 pelvic organ prolapse 10.9 TP53 PGR ESR2 ESR1
94 colorectal adenocarcinoma 10.9 VEGFA TP53 ERBB2 EGF
95 slipped capital femoral epiphysis 10.9 IGFBP3 IGF1
96 amelogenesis imperfecta, type ig 10.9 TFF1 PGR IGF1 ESR2 ESR1 ERBB2
97 uterine benign neoplasm 10.9 VEGFA TP53 PGR IGF1 ESR2 ESR1
98 reproductive organ benign neoplasm 10.9 VEGFA TP53 PGR IGF1 ESR2 ESR1
99 apocrine adenosis of breast 10.9 TP53 PGR ERBB2
100 breast papillary carcinoma 10.9 PGR ESR1 ERBB2
101 osteoporosis 10.9 VEGFA TP53 PGR IGFBP3 IGF1 ESR2
102 colon adenocarcinoma 10.9 VEGFA TP53 ESR2 ERBB2 EGF
103 autonomic nervous system neoplasm 10.9 VEGFA TP53 MIR199A1 ERBB2 EGF
104 gliosarcoma 10.9 VEGFA TP53 ERBB2 EGF
105 bizarre leiomyoma 10.9 TP53 PGR ESR1
106 peripheral nervous system neoplasm 10.9 VEGFA TP53 MIR199A1 ERBB2 EGF
107 teeth hard tissue disease 10.9 PGR IGF1 ESR2 ESR1 ERBB2 CYP19A1
108 amelogenesis imperfecta 10.9 PGR ESR2 ESR1 ERBB2 CYP19A1
109 breast metaplastic carcinoma 10.9 PGR ESR1 ERBB2
110 pancreatic adenocarcinoma 10.9 VEGFA TP53 RHOC IGF1 ESR1 ERBB2
111 tonsil cancer 10.9 TP53 PGR MIR199A1 ESR1 ERBB2
112 mixed cell type cancer 10.9 TP53 PGR ESR1 ERBB2 BRCA1
113 leiomyoma, uterine 10.9 PGR IGF1 ESR2 ESR1 EGF CYP19A1
114 postmenopausal atrophic vaginitis 10.9 ESR2 ESR1 CYP19A1
115 wilms tumor 1 10.9 VEGFA TP53 PGR IGF1 ESR1 ERBB2
116 breast adenoid cystic carcinoma 10.9 TP53 PGR ERBB2
117 adenomyosis 10.9 VEGFA TP53 PGR ESR2 ESR1 CYP19A1
118 urethral benign neoplasm 10.9 TP53 PGR ESR1
119 myoma 10.9 TP53 PGR ESR1 CYP19A1
120 central nervous system cancer 10.9 VEGFA TP53 MIR199A1 ERBB2 EGF
121 breast sarcoma 10.9 TP53 PGR ERBB2
122 progesterone-receptor negative breast cancer 10.9 PGR ESR1 ERBB2
123 adenosquamous carcinoma 10.9 TP53 PGR CTSD
124 endometrial hyperplasia 10.9 VEGFA TP53 PGR ESR2 ESR1 CYP19A1
125 glioblastoma multiforme 10.9 VEGFA TP53 RHOC IGF1 ESR1 ERBB2
126 lung cancer susceptibility 3 10.9 VEGFA TP53 MIR199A1 ESR2 ESR1 ERBB2
127 progesterone-receptor positive breast cancer 10.9 PGR ESR2 ESR1 ERBB2 CYP19A1
128 progesterone resistance 10.9 PGR ESR2 ESR1
129 squamous cell carcinoma 10.9 VEGFA TP53 ERBB2 EGF CYP1A1
130 apocrine sweat gland neoplasm 10.9 PGR ESR1 ERBB2
131 carpal tunnel syndrome 10.9 VEGFA PGR ESR1 COMT
132 ovarian cyst 10.9 VEGFA ESR2 CYP19A1
133 malignant spiradenoma 10.9 TP53 PGR ERBB2
134 lymphangioleiomyomatosis 10.9 VEGFA PGR IGF1 ESR1
135 breast osteosarcoma 10.9 PGR ESR1 ERBB2
136 intraductal breast benign neoplasm 10.9 PGR ESR1 ERBB2
137 cribriform carcinoma 10.9 PGR ESR1 ERBB2
138 mutagen sensitivity 10.9 TP53 IGF1 BRCA2 BRCA1
139 keratopathy 10.9 TP53 IGF1 CYP1B1
140 bile duct cancer 10.9 VEGFA TP53 MIR199A1 ERBB2 EGF
141 bone resorption disease 10.9 MIR199A1 IGF1 ESR2 ESR1 CYP19A1
142 bone remodeling disease 10.9 MIR199A1 IGF1 ESR2 ESR1 CYP19A1
143 leiomyosarcoma 10.9 VEGFA TP53 PGR ESR1
144 secondary adrenal insufficiency 10.9 IGFBP3 IGF1
145 ovarian carcinosarcoma 10.8 TP53 ERBB2 BRCA2 BRCA1
146 barrett esophagus 10.8 TP53 TFF1 ERBB2 CYP1A1
147 tongue squamous cell carcinoma 10.8 VEGFA TP53 RHOC EGF
148 endometrial serous adenocarcinoma 10.8 TP53 PGR ERBB2 BRCA1
149 sweat gland benign neoplasm 10.8 TP53 PGR ERBB2
150 vaginal adenoma 10.8 ESR2 CYP1A1 CYP19A1
151 medulloblastoma 10.8 VEGFA TP53 IGFBP3 ESR2 ERBB2 EGF
152 vaginal benign neoplasm 10.8 ESR2 CYP1A1 CYP19A1
153 gender identity disorder 10.8 PGR ESR2 ESR1 CYP19A1
154 mycetoma 10.8 CYP1B1 CYP19A1 COMT
155 mulchandani-bhoj-conlin syndrome 10.8 PGR ESR1 ERBB2 BRCA1
156 juvenile nasopharyngeal angiofibroma 10.8 VEGFA PGR ESR1 CYP19A1
157 thoracic benign neoplasm 10.8 TP53 PRLR PGR ESR1 ERBB2 EGF
158 tongue disease 10.8 VEGFA TP53 MIR199A1 EGF
159 breast benign neoplasm 10.8 TP53 PRLR PGR ESR1 ERBB2 EGF
160 lynch syndrome 10.8 TP53 IGF1 ERBB2 CYP1A1 BRCA2 BRCA1
161 endometriosis of ovary 10.8 PGR ESR2 ESR1 CYP19A1
162 suppression of tumorigenicity 12 10.8 VEGFA TP53 MIR199A1 IGFBP3 IGF1 ESR2
163 leukocyte disease 10.8 VEGFA TP53 MIR199A1 ERBB2
164 asperger syndrome 10.8 IGF1 ESR2 CYP19A1 COMT
165 salivary gland carcinoma 10.8 TP53 ESR2 ERBB2 BRCA1
166 esophageal cancer 10.8 VEGFA TP53 MIR199A1 IGFBP3 IGF1 ERBB2
167 nonmucinous bronchioloalveolar adenocarcinoma 10.8 ESR2 ESR1
168 endometrial stromal sarcoma 10.8 TP53 PGR ESR2 ESR1 CYP19A1
169 pancreatic ductal adenocarcinoma 10.8 VEGFA TP53 MIR199A1 ERBB2 EGF BRCA2
170 lung cancer 10.8 VEGFA TP53 MIR199A1 IGFBP3 IGF1 ESR2
171 germ cell cancer 10.8 MIR199A1 ESR2 ESR1 CYP1B1
172 functioning pituitary adenoma 10.8 PRLR MIR199A1 IGF1
173 fallopian tube disease 10.8 VEGFA TP53 BRCA2 BRCA1
174 estrogen-receptor negative breast cancer 10.8 VEGFA PGR IGF1 ESR1 ERBB2 EGF
175 autosomal genetic disease 10.8 VEGFA TP53 MIR199A1 IGF1 ESR2 ESR1
176 familial ovarian cancer 10.8 ESR1 BRCA2 BRCA1
177 estrogen-receptor positive breast cancer 10.8 VEGFA TP53 PGR ESR2 ESR1 ERBB2
178 oropharynx cancer 10.8 TP53 PGR MIR199A1 ERBB2
179 neuroblastoma 10.8 VEGFA TP53 IGF1 ESR1 ERBB2 EGF
180 ovarian cystadenocarcinoma 10.8 TP53 ERBB2 BRCA2 BRCA1
181 bartholin's gland adenoid cystic carcinoma 10.8 PGR ESR1
182 luminal breast carcinoma a 10.8 TP53 PGR ESR1 ERBB2 EGF CYP19A1
183 chronic tympanitis 10.8 PGR ESR1
184 ovarian clear cell adenocarcinoma 10.8 TP53 PGR ESR2
185 kidney cancer 10.8 VEGFA TP53 MIR199A1 EGF COMT
186 ovarian serous cystadenocarcinoma 10.8 VEGFA TP53 PGR ESR2 ESR1 ERBB2
187 cystadenocarcinoma 10.8 VEGFA TP53 PGR MIR199A1 ESR2 ERBB2
188 uterine corpus cancer 10.8 TP53 PGR ESR1 ERBB2 BRCA2 BRCA1
189 ovary adenocarcinoma 10.8 VEGFA TP53 PGR ESR1 ERBB2 EGF
190 primary pigmented nodular adrenocortical disease 10.8 PGR ESR2 ESR1 CYP19A1
191 adenoid cystic carcinoma 10.8 VEGFA TP53 PGR ERBB2 EGF BRCA1
192 squamous cell carcinoma, head and neck 10.8 VEGFA TP53 MIR199A1 ERBB2 EGF CYP1A1
193 esophagus adenocarcinoma 10.8 TP53 MIR199A1 ERBB2
194 cryptorchidism, unilateral or bilateral 10.8 IGF1 ESR2 ESR1 CYP19A1
195 primary peritoneal carcinoma 10.8 VEGFA TP53 PGR ERBB2 BRCA2 BRCA1
196 granulomatous endometritis 10.8 PGR ESR1
197 spinal disease 10.8 VEGFA TP53 MIR199A1 EGF
198 basaloid lung carcinoma 10.8 TP53 PGR BRCA2 BRCA1
199 papillary adenocarcinoma 10.8 TP53 PGR ERBB2 BRCA2 BRCA1
200 renal cell carcinoma, papillary, 1 10.8 VEGFA TP53 MIR199A1 ERBB2
201 oral cavity cancer 10.8 VEGFA MIR199A1 ERBB2 CYP1A1
202 endosalpingiosis 10.8 TP53 PGR BRCA2 BRCA1
203 rare breast tumor 10.8 TP53 ESR1 ERBB2 BRCA2 BRCA1
204 cervical adenoma malignum 10.8 TP53 PGR BRCA2 BRCA1
205 calcifying aponeurotic fibroma 10.8 PGR EGF
206 peritoneal mesothelioma 10.8 VEGFA PGR ESR1
207 gastric papillary adenocarcinoma 10.8 TP53 ERBB2
208 uterine corpus adenosarcoma 10.8 PGR ESR1
209 vaginal discharge 10.8 PGR ESR1 CYP19A1
210 hypertension, essential 10.8 VEGFA TP53 IGF1 ESR2 ESR1 EGF
211 obsessive-compulsive disorder 10.8 IGF1 ESR2 ESR1 COMT
212 papillary serous adenocarcinoma 10.8 TP53 PGR BRCA2 BRCA1
213 vaginal glandular tumor 10.8 PGR ESR1
214 mouth disease 10.8 TP53 MIR199A1 ESR2 ESR1
215 peritoneum cancer 10.8 TP53 BRCA2 BRCA1
216 scirrhous adenocarcinoma 10.8 PGR ERBB2
217 female reproductive endometrioid cancer 10.8 TP53 PGR MIR199A1 ESR1 ERBB2 BRCA2
218 leukemia, acute myeloid 10.8 VEGFA TP53 MIR199A1 ESR1 ERBB2 EGF
219 ovarian serous carcinoma 10.8 TP53 MIR199A1 ERBB2
220 colonic disease 10.8 TP53 MIR199A1 ESR1 CTSD
221 pediatric angiosarcoma 10.8 VEGFA TP53
222 synchronous bilateral breast carcinoma 10.8 PGR BRCA2 BRCA1
223 endometrial disease 10.8 PGR ESR1 CYP19A1
224 ovary epithelial cancer 10.8 VEGFA TP53 PGR MIR199A1 ESR1 ERBB2
225 malignant ovarian surface epithelial-stromal neoplasm 10.8 VEGFA TP53 PGR MIR199A1 ESR1 ERBB2
226 endometrial squamous cell carcinoma 10.8 TP53 PGR
227 colorectal cancer 2 10.8 VEGFA IGFBP3
228 myasthenic syndrome, congenital, 6, presynaptic 10.8 TP53 BRCA2 BRCA1
229 pre-malignant neoplasm 10.8 VEGFA TP53 PGR ESR1 ERBB2 EGF
230 lung leiomyoma 10.8 PGR ESR1
231 vulvar syringoma 10.8 PGR ESR1
232 serous cystadenocarcinoma 10.8 VEGFA TP53 PGR MIR199A1 ESR2 ERBB2
233 trigonitis 10.8 PGR ESR1
234 contractures, pterygia, and spondylocarpotarsal fusion syndrome 1a 10.8 VEGFA TP53 MIR199A1 BRCA2 BRCA1
235 fallopian tube clear cell adenocarcinoma 10.8 BRCA2 BRCA1
236 osteonecrosis 10.8 VEGFA IGF1 ESR1
237 brain cancer 10.8 VEGFA TP53 MIR199A1 EGF CYP1A1 BRCA2
238 endometrial cancer 10.8 VEGFA TP53 PGR MIR199A1 IGFBP3 IGF1
239 thoracic cancer 10.8 PGR MIR199A1 ESR1 ERBB2 BRCA1
240 mixed epithelial stromal tumour 10.8 CYP1B1 COMT
241 autosomal dominant polycystic kidney disease 10.8 VEGFA MIR199A1 IGF1 EGF
242 prostate cancer 10.8 VEGFA TP53 PRLR PGR MIR199A1 IGFBP3
243 ovarian cancer 10.8 VEGFA TP53 TFF1 PGR MIR199A1 IGFBP3
244 glycogen-rich clear cell breast carcinoma 10.8 PRLR PGR
245 bone cancer 10.8 TP53 PGR MIR199A1 ESR1
246 pituitary gland disease 10.8 PRLR IGFBP3 IGF1
247 cervical clear cell adenocarcinoma 10.8 PGR ESR1
248 pineal hyperplasia, insulin-resistant diabetes mellitus, and somatic abnormalities 10.8 IGFBP3 IGF1
249 bile duct cystadenoma 10.8 ESR2 ESR1
250 bladder cancer 10.8 VEGFA TP53 MIR199A1 ERBB2 EGF CYP1A1
251 mccune-albright syndrome 10.8 IGFBP3 IGF1 CYP19A1
252 ovary transitional cell carcinoma 10.8 BRCA2 BRCA1
253 diabetes mellitus, noninsulin-dependent 10.8 VEGFA TP53 MIR199A1 IGFBP3 IGF1 ESR2
254 premature menopause 10.7 CYP19A1 BRCA2 BRCA1
255 adult type testicular granulosa cell tumor 10.7 PGR ESR1
256 colorectal cancer 10.7 VEGFA TP53 MIR199A1 IGFBP3 IGF1 ESR2
257 uterine anomalies 10.7 TP53 MIR199A1 ESR1 CYP19A1
258 hereditary site-specific ovarian cancer syndrome 10.7 BRCA2 BRCA1
259 microvascular complications of diabetes 1 10.7 VEGFA IGFBP3 IGF1
260 peripheral nervous system disease 10.7 VEGFA TP53 IGF1 ERBB2
261 subserous uterine fibroid 10.7 PGR CYP19A1
262 esophagitis 10.7 VEGFA TP53 EGF
263 pleural disease 10.7 VEGFA TP53 MIR199A1
264 melanoma, uveal 10.7 VEGFA TP53 MIR199A1 BRCA1
265 tetraploidy 10.7 BRCA2 BRCA1
266 cancerophobia 10.7 BRCA2 BRCA1
267 breast juvenile papillomatosis 10.7 ERBB2 BRCA2
268 nosophobia 10.7 BRCA2 BRCA1
269 liver leiomyoma 10.7 PGR ESR1
270 benign metastasizing leiomyoma 10.7 PGR CYP19A1
271 intestinal benign neoplasm 10.7 VEGFA TP53 MIR199A1
272 retinal vascular disease 10.7 VEGFA MIR199A1 IGF1
273 endocrine organ benign neoplasm 10.7 TP53 MIR199A1 IGF1
274 peutz-jeghers syndrome 10.6 TP53 CYP19A1 BRCA2
275 intravenous leiomyomatosis 10.6 PGR ESR1
276 gallbladder cancer 10.6 VEGFA TP53 ERBB2 EGF
277 hepatocellular carcinoma 10.6 VEGFA TP53 RHOC MIR199A1 IGF1 ESR1
278 breast mucinous carcinoma 10.6 PGR ERBB2
279 parotid gland cancer 10.6 TP53 ERBB2
280 bile duct adenocarcinoma 10.6 TP53 MIR199A1 ERBB2
281 breast-ovarian cancer, familial 2 10.5 BRCA2 BRCA1
282 wolffian duct adenocarcinoma 10.5 TP53 ESR1
283 breast adenoma 10.5 PRLR PGR
284 pancreatic cancer 10.3 VEGFA TP53 TFF1 MIR199A1 ERBB2 EGF
285 papilloma 10.3
286 pituitary adenoma, prolactin-secreting 10.3 IGF1 ESR2 ESR1
287 squamous cell papilloma 10.2
288 lipomatosis, multiple 9.9
289 pleomorphic lipoma 9.9
290 granulomatous mastitis 9.9
291 lactocele 9.9
292 benign breast phyllodes tumor 9.9
293 adenoma 9.9
294 goiter 9.9
295 hyperprolactinemia 9.8
296 hypothyroidism 9.8
297 fibromatosis 9.8
298 congenital heart defects, hamartomas of tongue, and polysyndactyly 9.8
299 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 9.8
300 bent bone dysplasia syndrome 9.8
301 polycystic ovary syndrome 9.8
302 myopathy 9.8
303 premenstrual tension 9.8
304 48,xyyy 9.8
305 chromosomal triplication 9.8
306 epidermoid cysts 9.7
307 cowden syndrome 1 9.7
308 sarcoidosis 1 9.7
309 lymphoma, hodgkin, classic 9.7
310 lymphoma, non-hodgkin, familial 9.7
311 body mass index quantitative trait locus 1 9.7
312 anxiety 9.7
313 ptosis 9.7
314 dermatitis 9.7
315 proliferative type fibrocystic change of breast 9.7
316 thyroid gland disease 9.7
317 pregnancy adenoma 9.7
318 vasculitis 9.7
319 benign mammary dysplasia 9.7
320 autoimmune disease 9.5
321 hair whorl 9.5
322 otitis media 9.5
323 scleroderma, familial progressive 9.5
324 amelogenesis imperfecta, hypomaturation type, iia1 9.5
325 diabetes mellitus, type i 9.5
326 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 9.5
327 proteasome-associated autoinflammatory syndrome 1 9.5
328 arts syndrome 9.5
329 prostatic hyperplasia, benign 9.5
330 body mass index quantitative trait locus 9 9.5
331 body mass index quantitative trait locus 8 9.5
332 breast-ovarian cancer, familial 1 9.5
333 meningioma, radiation-induced 9.5
334 body mass index quantitative trait locus 4 9.5
335 body mass index quantitative trait locus 10 9.5
336 hypercholanemia, familial 9.5
337 body mass index quantitative trait locus 7 9.5
338 li-fraumeni syndrome 2 9.5
339 human immunodeficiency virus type 1 9.5
340 body mass index quantitative trait locus 12 9.5
341 sarcoidosis 2 9.5
342 body mass index quantitative trait locus 14 9.5
343 body mass index quantitative trait locus 18 9.5
344 melanoma, cutaneous malignant 10 9.5
345 sting-associated vasculopathy, infantile-onset 9.5
346 body mass index quantitative trait locus 19 9.5
347 body mass index quantitative trait locus 20 9.5
348 fibroma 9.5
349 sexual disorder 9.5
350 alexithymia 9.5
351 covid-19 9.5
352 sting-associated vasculopathy with onset in infancy 9.5
353 spinal meningioma 9.5
354 graves' disease 9.5
355 leukemia 9.5
356 nodular goiter 9.5
357 eclampsia 9.5
358 facial paralysis 9.5
359 lymphangioma 9.5
360 cholera 9.5
361 vascular disease 9.5
362 neuroendocrine carcinoma 9.5
363 melanoma 9.5
364 trichomoniasis 9.5
365 hyperinsulinism 9.5
366 cervicitis 9.5
367 prostatic adenoma 9.5
368 interstitial lung disease 9.5
369 papillary carcinoma 9.5
370 neurilemmoma 9.5
371 liposarcoma 9.5
372 histiocytosis 9.5
373 cellulitis 9.5
374 angiolipoma 9.5
375 thrombophlebitis 9.5
376 hidradenoma 9.5
377 secondary syphilis 9.5
378 syphilis 9.5
379 myofibroma 9.5
380 secretory meningioma 9.5
381 lymphoplasmacyte-rich meningioma 9.5
382 thyroiditis 9.5
383 pseudosarcomatous fibromatosis 9.5
384 bullous pemphigoid 9.5
385 herpes zoster 9.5
386 skin melanoma 9.5
387 fasciitis 9.5
388 alopecia 9.5
389 keloid disorder 9.5
390 47,xyy 9.5
391 cytokine deficiency 9.5
392 germ cells tumors 9.5
393 gigantomastia 9.5
394 granulomatous lobular mastitis 9.5
395 pyogenic granuloma 9.5
396 depression 9.5
397 back pain 9.5
398 supernumerary breasts 9.5
399 systemic autoimmune disease 9.5
400 rare lymphatic malformation 9.5
401 chronic enteropathy associated with slco2a1 gene 9.5
402 rare tumor 9.5
403 polyploidy 9.5
404 overgrowth syndrome 9.5
405 thyroid carcinoma 9.5
406 thyroid tumor 9.5

Graphical network of the top 20 diseases related to Breast Disease:



Diseases related to Breast Disease

Symptoms & Phenotypes for Breast Disease

UMLS symptoms related to Breast Disease:


pruritus, exanthema, pelvic pain, mastodynia, breast engorgement, nipple discharge, signs and symptoms in breast, other signs and symptoms in breast, breast pain female

MGI Mouse Phenotypes related to Breast Disease:

45 (showing 21, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.45 BRCA1 BRCA2 COMT CTSD CYP19A1 CYP1A1
2 homeostasis/metabolism MP:0005376 10.44 BRCA1 BRCA2 COMT CTSD CYP19A1 CYP1A1
3 cellular MP:0005384 10.42 BRCA1 BRCA2 CTSD CYP19A1 ERBB2 ESR1
4 growth/size/body region MP:0005378 10.41 BRCA1 BRCA2 CTSD CYP19A1 CYP1A1 EGF
5 behavior/neurological MP:0005386 10.4 BRCA1 BRCA2 COMT CTSD CYP19A1 ERBB2
6 hematopoietic system MP:0005397 10.34 BRCA1 BRCA2 COMT CTSD CYP19A1 CYP1A1
7 immune system MP:0005387 10.34 BRCA1 BRCA2 COMT CTSD CYP19A1 CYP1A1
8 cardiovascular system MP:0005385 10.32 BRCA1 COMT CYP19A1 ERBB2 ESR1 ESR2
9 integument MP:0010771 10.32 BRCA1 BRCA2 CTSD CYP19A1 EGF ERBB2
10 digestive/alimentary MP:0005381 10.31 BRCA1 BRCA2 CTSD CYP19A1 EGF ERBB2
11 neoplasm MP:0002006 10.22 BRCA1 BRCA2 CYP1B1 ERBB2 ESR1 ESR2
12 embryo MP:0005380 10.21 BRCA1 BRCA2 COMT ERBB2 ESR1 PGR
13 adipose tissue MP:0005375 10.2 BRCA1 CYP19A1 ESR1 ESR2 IGF1 IGFBP3
14 limbs/digits/tail MP:0005371 10.2 BRCA1 BRCA2 ERBB2 ESR1 ESR2 IGF1
15 nervous system MP:0003631 10.18 BRCA1 BRCA2 COMT CTSD CYP19A1 ERBB2
16 muscle MP:0005369 10.13 BRCA1 CYP19A1 ERBB2 ESR1 ESR2 IGF1
17 normal MP:0002873 10.1 BRCA1 BRCA2 CYP19A1 CYP1A1 EGF ERBB2
18 reproductive system MP:0005389 9.97 BRCA1 BRCA2 COMT CYP19A1 EGF ERBB2
19 renal/urinary system MP:0005367 9.86 BRCA1 COMT CYP19A1 ESR1 ESR2 IGF1
20 respiratory system MP:0005388 9.56 BRCA1 COMT ERBB2 ESR1 ESR2 IGF1
21 skeleton MP:0005390 9.4 BRCA1 BRCA2 CYP19A1 ERBB2 ESR1 ESR2

Drugs & Therapeutics for Breast Disease

Drugs for Breast Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 178, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
2
Tamoxifen Approved Phase 4 10540-29-1 2733526
3
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
4
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
5
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
6
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
7 abobotulinumtoxinA Phase 4
8 Cholinergic Agents Phase 4
9 Botulinum Toxins Phase 4
10 Botulinum Toxins, Type A Phase 4
11 Neurotransmitter Agents Phase 4
12 retinol Phase 4
13 Retinol palmitate Phase 4
14 Evening Primrose Phase 4
15 Lipid Regulating Agents Phase 4
16 Estrogen Receptor Modulators Phase 4
17 Analgesics, Non-Narcotic Phase 4
18 Hypolipidemic Agents Phase 4
19 Anti-Inflammatory Agents, Non-Steroidal Phase 4
20 Anesthetics, General Phase 4
21 Anesthetics, Local Phase 4
22 Anti-Inflammatory Agents Phase 4
23 Dermatologic Agents Phase 4
24 Respiratory System Agents Phase 4
25 glucocorticoids Phase 4
26 Hydrocortisone 17-butyrate 21-propionate Phase 4
27 Anti-Asthmatic Agents Phase 4
28 Hydrocortisone-17-butyrate Phase 4
29 Hydrocortisone hemisuccinate Phase 4
30 Betamethasone sodium phosphate Phase 4
31 Betamethasone Valerate Phase 4 2152-44-5
32 Betamethasone-17,21-dipropionate Phase 4
33 Betamethasone benzoate Phase 4
34 Chelating Agents Phase 4
35 Gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate Phase 4
36
Evening primrose oil Investigational, Nutraceutical Phase 4 308064-97-3
37
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
38
Epirubicin Approved Phase 2, Phase 3 56420-45-2 41867
39
Goserelin Approved Phase 2, Phase 3 65807-02-5 5311128 47725
40
Remifentanil Approved Phase 3 132875-61-7 60815
41
Propofol Approved, Investigational, Vet_approved Phase 3 2078-54-8 4943
42
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
43
tannic acid Approved Phase 3 1401-55-4
44
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
45
Acetaminophen Approved Phase 3 103-90-2 1983
46
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
47
Codeine Approved, Illicit Phase 3 76-57-3 5284371
48
Celecoxib Approved, Investigational Phase 3 169590-42-5 2662
49
Atezolizumab Approved, Investigational Phase 3 1380723-44-3
50
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
51
Fulvestrant Approved, Investigational Phase 3 129453-61-8 104741 17756771
52
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
53
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
54
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
55
Lenograstim Approved, Investigational Phase 3 135968-09-1
56
Bevacizumab Approved, Investigational Phase 3 216974-75-3
57 Immunologic Factors Phase 3
58 Immunosuppressive Agents Phase 2, Phase 3
59 Aromatase Inhibitors Phase 2, Phase 3
60 Analgesics Phase 3
61 Narcotics Phase 3
62 Analgesics, Opioid Phase 3
63 Protective Agents Phase 3
64 Sodium Channel Blockers Phase 3
65 Anti-Arrhythmia Agents Phase 3
66 Diuretics, Potassium Sparing Phase 3
67 2,2'-dithiodiethanesulfonic acid Phase 3
68 Antitussive Agents Phase 3
69 Chlorpheniramine, phenylpropanolamine drug combination Phase 3
70 Cyclooxygenase Inhibitors Phase 3
71 Antipyretics Phase 3
72 Pharmaceutical Solutions Phase 3
73 Cyclooxygenase 2 Inhibitors Phase 3
74 Immunoglobulins Phase 3
75 Antibodies Phase 3
76 Antibodies, Monoclonal Phase 3
77 Antirheumatic Agents Phase 3
78 Tubulin Modulators Phase 3
79 Antimitotic Agents Phase 3
80 Antineoplastic Agents, Immunological Phase 3
81 Anti-Bacterial Agents Phase 3
82 Antibiotics, Antitubercular Phase 3
83 Alkylating Agents Phase 3
84
Liposomal doxorubicin Phase 3 31703
85 Triamcinolone diacetate Phase 3
86 Triamcinolone hexacetonide Phase 3
87 triamcinolone acetonide Phase 3
88 Angiogenesis Inhibitors Phase 3
89
Danazol Approved Phase 2 17230-88-5 28417
90
Iodine Approved, Investigational Phase 2 7553-56-2 807
91
Lidocaine Approved, Vet_approved Phase 2 137-58-6 3676
92
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
93
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
94
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
95
Zoledronic Acid Approved Phase 2 118072-93-8 68740
96
Simvastatin Approved Phase 2 79902-63-9 54454
97
Leflunomide Approved, Investigational Phase 1, Phase 2 75706-12-6 3899
98
Pertuzumab Approved Phase 1, Phase 2 380610-27-5, 145040-37-5 2540
99
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
100
Progesterone Approved, Vet_approved Phase 2 57-83-0 5994
101
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
102
Anastrozole Approved, Investigational Phase 2 120511-73-1 2187
103
Exemestane Approved, Investigational Phase 2 107868-30-4 60198
104
Oxytocin Approved, Vet_approved Phase 2 50-56-6 53477758 439302
105
Lapatinib Approved, Investigational Phase 2 231277-92-2, 388082-78-8 208908 9941095
106
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
107
Maleic acid Experimental, Investigational Phase 2 110-17-8, 110-16-7 444972
108 Omega 3 Fatty Acid Phase 2
109 Estrogen Antagonists Phase 2
110 Estrogen Receptor Antagonists Phase 2
111 Estrogens Phase 2
112 Antineoplastic Agents, Hormonal Phase 2
113 cadexomer iodine Phase 2
114 Antidotes Phase 2
115 Charcoal Phase 2
116 Vaccines Phase 2
117 taxane Phase 2
118 Soy Bean Phase 2
119 Guarana Phase 2
120 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 2
121 Anticholesteremic Agents Phase 2
122 Hormones Phase 2
123 Hormone Antagonists Phase 2
124 Antimetabolites Phase 2
125 Progestins Phase 2
126 Protein Kinase Inhibitors Phase 2
127
Pembrolizumab Approved Phase 1 1374853-91-4
128
Sargramostim Approved, Investigational Phase 1 83869-56-1, 123774-72-1
129
Metronidazole Approved Phase 1 443-48-1 4173
130
Entinostat Investigational Phase 1 209783-80-2